Evidence item

Independent oncology coverage confirms the 166-patient LONESTAR randomization and non-significant overall- and progression-free-survival results, including the reported hazard ratios. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 19379

Source: Local Consolidation Therapy Following ICI Induction Did Not Improve Survival in Metastatic NSCLC · locator {} · excerpt hash sha256:1233600646c7dec81020dcb7ed06d5d56c7c15882d3bd48cc5961a44fefff8a6

Exact excerpt

During an average follow-up of 35.7 to 39.3 months, the median OS was 43.2 months ... with local consolidation therapy and 52.8 months ... ipilimumab/nivolumab (hazard ratio [HR], 1.14; 95% CI, 0.75-1.74; P = .54). ... The addition of local consolidation therapy was not supported by the secondary outcomes of progression-free survival (PFS) in the whole study population (HR, 0.79; 95% CI, 0.54-1.15; P = .22).

Linked claims

Claim	Direction	Relevance	Steps	Counted
7e7d05e6	SUPPORT	STRONG	0	yes

Audits

None.